Latest stories on PPBT
Purple Biotech GAAP EPS of -$0.51
Seeking Alpha38 · neutralearnings
Purple Biotech Reports Third Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire58 · neutralearnings
Purple Biotech Reports Third Quarter 2026 Financial Results and Provides Business Update
Business Insider58 · neutralearnings
Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium
GlobeNewswire56 · neutralproduct/pr
Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium
StockTitan56 · neutralproduct/pr
Purple Biotech Reinstates Isaac Israel as Interim CEO in Leadership Reshuffle
TipRanks55 · neutralgeneral
3 Penny Stocks on Investors’ Radar after Big Moves, 9/03/26
TipRanks54 · neutralgeneral
Why Is Purple Biotech (PPBT) Stock 42% Up Today?
TipRanks68 · bullishgeneral
Purple Biotech Gains New U.S. Patent Allowance for CAPTN-3 Cancer Immunotherapy Platform
TipRanks63 · neutralproduct/pr
Purple Biotech issued notice of allowance from USPTO
The Fly63 · neutralgeneral
H.C. Wainwright cuts Purple Biotech stock price target on preclinical progress
Investing.com Analyst Ratings38 · neutralanalyst
Purple Biotech price target lowered to $17 from $30 at H.C. Wainwright
The Fly34 · bearishanalyst
Purple Biotech GAAP EPADS of -$0.41
Seeking Alpha28 · bearishearnings
Purple Biotech Reports Second Quarter 2026 Financial Results
Business Insider59 · neutralearnings
Purple Biotech Reports Second Quarter 2026 Financial Results
StockTitan59 · neutralearnings
Purple Biotech Updates Investors on CAPTN-3 Platform and Pipeline as IM1240 Nears 2027 Clinic Entry
TipRanks56 · neutralproduct/pr
Purple Biotech GAAP EPS of -$0.09
Seeking Alpha28 · bearishearnings